Daily Cosmetic Research Analysis
A multicenter randomized trial showed that casting alone is noninferior to surgery for pediatric medial epicondyle fractures at 12 months, with better cosmetic ratings despite higher radiographic nonunion. An exposure assessment revealed that “n-free” nail polishes still generated measurable formaldehyde, toluene, and benzene in the manicurist breathing zone. A network meta-analysis in antihistamine-refractory chronic spontaneous urticaria supported omalizumab 300 mg and oral remibrutinib as lea
Summary
A multicenter randomized trial showed that casting alone is noninferior to surgery for pediatric medial epicondyle fractures at 12 months, with better cosmetic ratings despite higher radiographic nonunion. An exposure assessment revealed that “n-free” nail polishes still generated measurable formaldehyde, toluene, and benzene in the manicurist breathing zone. A network meta-analysis in antihistamine-refractory chronic spontaneous urticaria supported omalizumab 300 mg and oral remibrutinib as leading options with favorable efficacy and safety.
Research Themes
- Nonoperative versus operative care in pediatric fractures
- Cosmetic product safety and occupational exposure
- Comparative effectiveness of targeted therapies in dermatologic disease
Selected Articles
1. Casting vs Surgical Treatment of Children With Medial Epicondyle Fractures: A Randomized Clinical Trial.
In a multicenter noninferiority RCT (n=72), long-arm casting was noninferior to open reduction and internal fixation for displaced pediatric medial epicondyle fractures at 12 months by QDASH. Cosmetic ratings favored casting, while radiographic nonunion was far more common with casting but without functional detriment at 1 year.
Impact: High-quality randomized evidence challenges increased surgical use and supports casting as an effective first-line option. Cosmetic outcomes and functional parity may influence shared decision-making.
Clinical Implications: Nonoperative casting can be offered confidently for displaced medial epicondyle fractures with counseling on high nonunion rates and the lack of short-term functional harm. Surgical indications should be individualized, and long-term outcomes monitored.
Key Findings
- Casting was noninferior to surgery for 12-month QDASH (mean difference −0.98; 95% CI −2.95 to 0.98).
- Cosmetic visual analog scale scores favored casting (between-group difference −8.9; 95% CI −16.6 to −1.2).
- Radiographic nonunion was 68.6% with casting versus 2.7% with surgery; no crossovers occurred.
Methodological Strengths
- Multicenter randomized noninferiority design with intention-to-treat analysis
- Prospective registration (ClinicalTrials.gov NCT04531085) and clear primary endpoint
Limitations
- Sample size modest (n=72) and 12-month horizon; longer-term functional impact of nonunion unknown
- Cosmetic and function outcomes may be influenced by lack of blinding
Future Directions: Evaluate long-term functional, cosmetic, and return-to-sport outcomes, and define subgroups that benefit from surgery versus casting.
IMPORTANCE: Displaced pediatric medial humeral epicondyle fractures are traditionally treated nonoperatively with casting. However, the use of surgical treatment has increased despite limited high-level evidence supporting its benefits. OBJECTIVE: To determine whether open surgical reduction and internal fixation improve functional outcomes compared with long arm casting in children with displaced medial humeral epicondyle fractures at 12 months post injury. DESIGN, SETTING, AND PARTICIPANTS: This noninferiority randomized clinical trial was conducted in 4 university hospitals in Finland between August 30, 2019, and August 22, 2023, with a 12-month follow-up completed August 20, 2024. Participants included children (aged 7-16 years) with nonincarcerated medial humeral epicondyle fractures and more than 2 mm of displacement. Data analysis was based on intention to treat. INTERVENTIONS: Open reduction and fixation, followed by a long arm cast for 4 weeks, or long arm cast without reduction for 4 weeks. MAIN OUTCOME AND MEASURE: The primary outcome was the Quick Disabilities of the Arm, Shoulder, and Hand (QDASH) score at 12 months (range, 0-100 points, with 0 denoting no disability and 100 extreme disability; prespecified noninferiority margin was 6.8 points). RESULTS: Seventy-two patients were randomized (43 [59.7%] female; mean [SD] age, 12.1 [2.1] years; range, 7.9-15.9 years), with 37 (19 [51.4%] female) to the surgery group (mean [SD] age, 12.2 [2.3] years; range, 7.9-15.9 years) and 35 (24 [68.6%] female) to the cast group (mean [SD] age, 11.9 [2.0] years; range 7.9-15.9 years). At 12 months, the mean QDASH score was 1.73 (95% CI, 0.65-2.81) in the surgery group and 2.71 (95% CI, 0.52-4.90) in the cast group, showing noninferiority (mean difference, -0.98 [95% CI, -2.95 to 0.98] points). The cosmetic visual analog scale favored the cast group, with a statistically significant between-group difference of -8.9 points (95% CI, -16.6 to -1.2 points; P < .001). Nonunion occurred in 1 of 37 surgically treated patients (2.7%) and 24 of 35 cast-treated patients (68.6%). No crossovers from casting to surgery occurred. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of displaced medial epicondyle fractures, treatment with casting alone was noninferior at 12 months to surgical reduction and internal fixation followed by casting. Findings support nonoperative care as effective at 1 year; longer-term outcomes remain to be studied. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04531085.
2. Biological and target synthetic treatments for chronic spontaneous urticaria: A systematic review and network meta-analysis.
Across 23 RCTs (n=6933), omalizumab 300 mg consistently outperformed placebo for UAS7, and oral remibrutinib (10–35 mg regimens) showed strong efficacy-safety balance. Dupilumab and several BTK inhibitors also exceeded placebo, with no significant safety differences across agents.
Impact: Provides comparative, aggregated evidence to guide agent selection in antihistamine-refractory CSU, highlighting both a biologic (omalizumab) and an oral small molecule (remibrutinib).
Clinical Implications: Clinicians can preferentially consider omalizumab 300 mg or oral remibrutinib regimens for CSU unresponsive to antihistamines, while monitoring patient-specific factors and access.
Key Findings
- Omalizumab 300 mg achieved a mean UAS7 reduction vs placebo of −10.07 (95% CI −11.35 to −8.82).
- Remibrutinib (35 mg QD, 25 mg BID, 10 mg BID) ranked highly for combined efficacy and safety.
- Dupilumab, fenebrutinib, and rilzabrutinib were also superior to placebo; no significant AE/SAE differences across treatments.
Methodological Strengths
- Network meta-analysis of 23 randomized trials with 6933 participants
- PROSPERO-registered protocol and consistent efficacy endpoints (UAS7, response thresholds)
Limitations
- Heterogeneity in dosing regimens and trial populations; indirect comparisons inherent to NMA
- Limited long-term safety and durability data across agents
Future Directions: Head-to-head trials between top-ranked agents, long-term safety/relapse data, and subgroup analyses (e.g., IgE levels, biomarkers) to personalize therapy.
BACKGROUND: Most biological and synthetic target-specific drugs for antihistamine-refractory chronic spontaneous urticaria (CSU) have not been compared head-to-head. This systematic review and network meta-analysis evaluated their relative efficacy and safety. METHODS: Searches were conducted on PubMed, Embase, Web of Science and Cochrane library databases to March 25, 2024 for randomized trials. A random-effects model was used to calculate the network estimates reported as mean differences (MD) and odds ratios (OR) with corresponding 95% CIs. Main outcomes included the weekly urticaria activity score (UAS7), adverse events (AEs) and serious adverse events (SAEs). RESULTS: 23 randomized clinical trials with 6933 participants that compared 26 different interventions or dosages and placebos were included. Omalizumab 300 mg [MD -10.07, 95% CI (-11.35; -8.82)] continues to demonstrate superior efficacy compared with placebo. Remibrutinib, at doses of 35 mg once daily [MD -7.80, 95% CI (-12.76; -2.51)], 25 mg twice daily [MD -7.69, 95% CI (-9.85; -5.76)], and 10 mg twice daily [MD -7.61, 95% CI (-12.59; -2.47)], had the best overall performance for efficacy and safety. Dupilumab, fenebrutinib, and rilzabrutinib also showed greater efficacy than placebo. The results were similar for the proportion of patients who achieved UAS7 ≤ 6 or UAS7 = 0. No significant differences were found among all treatment comparisons for AEs and SAEs. CONCLUSION: The findings of this study indicate that the biological agent omalizumab 300 mg and the oral small molecule remibrutinib at doses of 35 mg, 25 mg, or 10 mg are recommended for patients with antihistamine-refractory CSU. TRIAL REGISTRATION: PROSPERO: CRD42024516289.
3. Evaluation of chemical exposures generated from n-free nail polishes.
In a controlled exposure-chamber study of 20 “n-free” nail polishes, real-time FTIR detected formaldehyde and toluene in all products and benzene at varying levels in the manicurist breathing zone. Exposures did not significantly differ across products, underscoring persistent VOC risks despite “3-free” claims.
Impact: Provides quantitative, breathing-zone exposure data contradicting marketing claims and informing occupational health protections for nail salon workers.
Clinical Implications: Advocate for improved ventilation, exposure controls, and transparent ingredient disclosure; consider worker education and policy updates addressing VOCs in “n-free” products.
Key Findings
- Formaldehyde and toluene were detected by real-time FTIR in all “3-free” labeled polishes tested.
- Breathing-zone benzene exposures were measurable across products (GM 0.076–0.752 ppm/g).
- No significant differences in formaldehyde, toluene, or benzene exposures between products; DBP and TPhP were not detected.
Methodological Strengths
- Breathing-zone measurements using real-time FTIR and PID with time-integrated sampling
- Controlled exposure-chamber protocol with standardized two-coat application and 2-hour post-application monitoring
Limitations
- Exposure-chamber setting may not fully replicate real salon variability (ventilation, room size, workflow)
- Ingredient lists for salon-only products were unavailable; only 20 products tested
Future Directions: Real-world salon studies across ventilation scenarios, longitudinal biomonitoring, and regulatory evaluation of labeling standards for VOC emissions.
Nail polishes contain over a dozen chemical compounds, including chemicals that can cause adverse reproductive outcomes and pose a risk to the high proportion of nail salon workers who are women of childbearing age. Consumer demand has resulted in a shift toward more natural products, with manufacturers attempting to remove harmful ingredients (n-free products). Many products that claim to have eliminated toluene, formaldehyde, and dibutyl phthalate (DBP) are labeled as "3-free"; however, studies have found these products often contain higher concentrations of toluene and DBP compared to products with no such claims. Products used only at salons are not required to list ingredients, leading to uncertainties as to the exact chemical composition and potential exposures. A better understanding of chemical exposures associated with nail polish products is necessary to understand potential worker exposures and develop effective control options. This study evaluated chemical exposures generated while painting nails with 20 n-free polishes using real-time and time-integrated air sampling. Total volatile organic compounds (TVOCs, PID, ION Science Inc.) and 22 individual compounds (FTIR, Gasmet Technologies) were measured in the breathing zone of the manicurist while two coats of polish were applied to artificial nails on a manikin in an exposure chamber and for 2 hr afterwards. Formaldehyde and toluene were measured in all polishes using the real-time FTIR, despite all claiming to be 3-free. Normalized geometric mean (GM) formaldehyde exposures from the FTIR ranged from 0.021 to 0.273 ppm/g, GM toluene exposures ranged from 0.068 to 0.534 ppm/g, and GM benzene exposures ranged from 0.076 to 0.752 ppm/g. Notably, formaldehyde, toluene, and benzene exposures did not significantly differ between different products. Neither DBP nor triphenyl phosphate (TPhP) was detected in any of the polishes. This study highlights that despite industry claims, n-free polishes may still contain chemicals associated with negative health effects and that more studies are necessary to understand the true chemical exposures of nail salon workers.